Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03632226 · ClinicalTrials.gov registry record
Evaluation of a Novel PET Radioligand to Image OGA
A clinical trial, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 28
- Enrollment target
NCT03632226 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 28 participants.
The verdict
NCT03632226 has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
Background: O-GlcNAcase (OGA) is a brain enzyme. It may play a role in brain disorders like Alzheimer s disease. Researchers want to see if a new drug can be used with positron emission tomography (PET) scans to show OGA better. Researchers want to learn more about how it acts in healthy people. Objectives: To test if the new drug \[18F\]OGA-1 can measure its receptor. To determine whether the same results occur when scanning a person twice. Eligibility: Healthy adults age 18 and older who are already enrolled in a separate protocol. Design: Some participants will have 1 whole-body PET scan during one 4-hour visit to the clinic. Some will have 2-3 brain scans (PET and MRI) over 2-3 days. For the PET scan, a needle will guide a thin plastic tube (IV catheter) into an arm vein. A small amount of radioactive chemical will be injected through the catheter. The needle will be removed. Only the catheter will be left in the vein. Another IV catheter may be placed to draw blood. Blood pressure, heart rate, and breathing rate will be measured. Participants will have an electrocardiogram. Participants will lie on a bed that slides in and out of the donut-shaped scanner. The scan will last 2-3 hours. For brain PET scan, participants will wear a plastic mask to keep their head still. For magnetic resonance imaging (MRI) scan, participants will lie on a table. The table slides in and out of the MRI scanner. This is a metal cylinder in a strong magnetic field. Participants will be in the scanner up to 1 hour.
Interventions
- DRUG 18F-OGA-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-05-02 |
| Est. Completion | 2019-06-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03632226
The ClinicalTrials.gov registry entry for NCT03632226 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-OGA-1 is the first listed.
NCT03632226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03632226 about?
NCT03632226 is a clinical study titled "Evaluation of a Novel PET Radioligand to Image OGA". Background: O-GlcNAcase (OGA) is a brain enzyme. It may play a role in brain disorders like Alzheimer s disease. Researchers want to see if a new drug can be used with positron emission tomography (PET) scans to show OGA better. Researchers want to learn more about how it acts in healthy people. O...
What is the current status of trial NCT03632226?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2016-05-02. Estimated completion is 2019-06-25.
What interventions are being tested in trial NCT03632226?
The interventions under investigation include: 18F-OGA-1 (DRUG).
Who is sponsoring clinical trial NCT03632226?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.